JP2020536887A - Ｐａｒｐ阻害剤およびｐｄ−１系結合アンタゴニストの組合せ - Google Patents

Ｐａｒｐ阻害剤およびｐｄ−１系結合アンタゴニストの組合せ Download PDF

Info

Publication number
JP2020536887A
JP2020536887A JP2020520007A JP2020520007A JP2020536887A JP 2020536887 A JP2020536887 A JP 2020536887A JP 2020520007 A JP2020520007 A JP 2020520007A JP 2020520007 A JP2020520007 A JP 2020520007A JP 2020536887 A JP2020536887 A JP 2020536887A
Authority
JP
Japan
Prior art keywords
cancer
ddr
patient
treatment
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020520007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536887A5 (enExample
Inventor
ブレイク−ハスキンス，ジョン・アンドリュー
ボショフ，クリストッフェル・ヘンドリク
チェザリ，ロッサーノ
ナイテン，ディミトリー・サージ・アントニー
スチュワート，ロス・アンソニー
ゾーレン，ファビアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2020536887A publication Critical patent/JP2020536887A/ja
Publication of JP2020536887A5 publication Critical patent/JP2020536887A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020520007A 2017-10-13 2018-10-10 Ｐａｒｐ阻害剤およびｐｄ−１系結合アンタゴニストの組合せ Withdrawn JP2020536887A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762572024P 2017-10-13 2017-10-13
US62/572,024 2017-10-13
US201862697587P 2018-07-13 2018-07-13
US62/697,587 2018-07-13
PCT/US2018/055174 WO2019075032A1 (en) 2017-10-13 2018-10-10 COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST

Publications (2)

Publication Number Publication Date
JP2020536887A true JP2020536887A (ja) 2020-12-17
JP2020536887A5 JP2020536887A5 (enExample) 2021-09-02

Family

ID=64049735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520007A Withdrawn JP2020536887A (ja) 2017-10-13 2018-10-10 Ｐａｒｐ阻害剤およびｐｄ−１系結合アンタゴニストの組合せ

Country Status (13)

Country Link
US (1) US20200254091A1 (enExample)
EP (1) EP3694551A1 (enExample)
JP (1) JP2020536887A (enExample)
KR (1) KR20200071097A (enExample)
CN (1) CN111225685A (enExample)
AU (1) AU2018347331A1 (enExample)
BR (1) BR112020006371A2 (enExample)
CA (1) CA3078806A1 (enExample)
IL (1) IL273994A (enExample)
MX (1) MX2020003361A (enExample)
RU (1) RU2020113246A (enExample)
TW (1) TW201922288A (enExample)
WO (1) WO2019075032A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510666A (ja) * 2021-03-24 2024-03-08 ファイザー・インク Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190062515A (ko) * 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CN113116881B (zh) * 2019-12-31 2025-03-07 甫康（上海）健康科技有限责任公司 一种用于治疗肿瘤的药物组合及其应用
JP2023524270A (ja) * 2020-05-04 2023-06-09 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｄ－１アンタゴニスト、化学放射線療法およびｐａｒｐ阻害剤の組み合わせを用いた癌の治療方法
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN104478875B (zh) 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
EP2531033A4 (en) 2010-02-03 2013-07-31 Biomarin Pharm Inc POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
KR20190120458A (ko) 2010-10-21 2019-10-23 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN105916846A (zh) 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 用于合成经保护的n-烷基三唑甲醛的三唑中间体
PL3102605T3 (pl) * 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
EP3563870A1 (en) * 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
CN107206088A (zh) * 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
RU2714233C2 (ru) * 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
MX2017015937A (es) * 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
SG11201803462PA (en) 2015-10-26 2018-05-30 Medivation Tech Llc Treatment of small cell lung cancer with a parp inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510666A (ja) * 2021-03-24 2024-03-08 ファイザー・インク Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ

Also Published As

Publication number Publication date
AU2018347331A1 (en) 2020-04-09
RU2020113246A (ru) 2021-11-15
BR112020006371A2 (pt) 2020-09-29
WO2019075032A1 (en) 2019-04-18
EP3694551A1 (en) 2020-08-19
RU2020113246A3 (enExample) 2021-11-15
MX2020003361A (es) 2020-07-29
KR20200071097A (ko) 2020-06-18
US20200254091A1 (en) 2020-08-13
CA3078806A1 (en) 2019-04-18
IL273994A (en) 2020-05-31
TW201922288A (zh) 2019-06-16
CN111225685A (zh) 2020-06-02

Similar Documents

Publication Publication Date Title
JP2020536887A (ja) Ｐａｒｐ阻害剤およびｐｄ−１系結合アンタゴニストの組合せ
JP7534344B2 (ja) 癌のための治療方法及び診断方法
ES2789500T5 (es) Procedimientos terapéuticos y de diagnóstico para el cáncer
CA3165187A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
JP2021507904A (ja) 癌を処置するための方法および併用療法
JP2018508183A (ja) 化学療法耐性癌を治療及び診断する組成物及び方法
TW201639597A (zh) 用於治療癌症之ｐｄ－１／ｐｄ－ｌ１抑制劑
CN108350081A (zh) 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
TW202023617A (zh) 膀胱癌之治療及診斷方法
US20190216923A1 (en) Methods and combination therapy to treat cancer
US20200368205A1 (en) Methods and combination therapy to treat cancer
WO2019139583A1 (en) Methods and combination therapy to treat cancer
WO2020223233A1 (en) Prognostic and therapeutic methods for colorectal cancer
US20190211102A1 (en) Methods and combination therapy to treat cancer
HK40019847A (en) Combination of a parp inhibitor and a pd-1 axis binding antagonist
WO2025085404A1 (en) Diagnostic and therapeutic methods for treating lung cancer
TW202320848A (zh) 治療癌症之方法及組成物
WO2025024257A1 (en) Diagnostic and therapeutic methods for cancer
HK40028739A (en) Methods and combination therapy to treat cancer
HK40031470A (en) Methods and combination therapy to treat cancer
PA session A: gastrointestinal tumours

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210726

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210916